Recruiting studies: Recurrent Metastatic Head And Neck Squamous Cell Carcinoma R

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06597565 Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and
Phase N/A · 1 location(s) · University of Rome Tor Vergata · NCT07448727 Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 · 2 location(s) · Eye & ENT Hospital of Fudan University · NCT05260671 A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698 Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R
Phase 2 · 8 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06869473 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Dan Zandberg · NCT06052839 H101 Plus TACE for r/m HNSCC
Phase 2 · 1 location(s) · West China Hospital · NCT07398664 PDO Based Drug Sensitive Test in R/M HNSCC
Phase N/A · 2 location(s) · Huashan Hospital · NCT06686342 Window of Opportunity in Preserving Laryngeal Function Trial
Phase 2 · 1 location(s) · Matthew Spector · NCT07423078 Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Phase 2 · 1 location(s) · Yuankai Shi · NCT04857164 FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos,
Phase 2/Phase 3 · 203 location(s) · Bicara Therapeutics · NCT06788990 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499 A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Res
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT07408063 Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06935188 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinom
Phase 3 · 2 location(s) · Akeso · NCT06601335 A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative He
Phase 3 · 112 location(s) · AVEO Pharmaceuticals, Inc. · NCT06064877

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.